ArticleSmall (Weinheim an der Bergstrasse, Germany)2013
An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells.
Article in Small (Weinheim an der Bergstrasse, Germany), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 67 citations in OpenAlex.
- Aptamers in Drug Delivery Development.Materials today (Kidlington, England) · 2025Article
- Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer.Molecular and cellular biochemistry · 2023Review
- Natural and synthetic nanovectors for cancer therapy.Nanotheranostics · 2023Review
- Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.International journal of molecular sciences · 2020Review
- Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases.International journal of molecular sciences · 2020Review
- Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy.International journal of molecular sciences · 2020Review
- Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies.Molecular therapy. Nucleic acids · 2018Review
- Review
- Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells.ACS omega · 2017Article
- Advances in the development of aptamer drug conjugates for targeted drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2017Review
- Laser-Triggered Small Interfering RNA Releasing Gold Nanoshells against Heat Shock Protein for Sensitized Photothermal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Article
- Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells.Theranostics · 2017Review
- Recent Methods for Purification and Structure Determination of Oligonucleotides.International journal of molecular sciences · 2016Review
- Aptamer-Mediated Targeted Delivery of Therapeutics: An Update.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Application of aptamers in diagnostics, drug-delivery and imaging.Journal of biosciences · 2016Article
- Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials · 2015Article
- Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.Biomedicines · 2015Review
- CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy.ACS nano · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Nanotechnology has often been applied in the development of targeted drug-delivery systems for the treatment of cancer. An ideal nanoscale system for drug delivery should be able to selectively deliver and rapidly release the carried therapeutic drug(s) in cancer cells and, more importantly, not react to off-target cells so as to eliminate unwanted toxicity on normal tissues. To reach this goal, a selective chemotherapeutic is formulated using a hollow gold nanosphere (HAuNS) equipped with a biomarker-specific aptamer (Apt), and loaded with the chemotherapy drug doxorubicin (DOX). The formed Apt-HAuNS-Dox, approximately 42 nm in diameter, specifically binds to lymphoma tumor cells and does not react to control cells that do not express the biomarker. Through aptamer-mediated selective cell binding, the Apt-HAuNS-Dox is internalized exclusively into the targeted tumor cells, and then released the DOX intracellularly. Of note, although the formed Apt-HAuNS-Dox is stable under normal biological conditions (pH 7.4), it appears ultrasensitive to pH change and rapidly releases 80% of the loaded DOX within 2 h at pH 5.0, a condition seen in cell lysosomes. Functional assays using cell mixtures show that the Apt-HAuNS-Dox selectively kills lymphoma tumor cells, but has no effect on the growth of the off-target cells in the same cultures, indicating that this ultra pH-sensitive Apt-HAuNS-Dox can selectively treat cancer through specific aptamer guidance, and will have minimal side effects on normal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.